Kyverna Therapeutics Files 2025 Proxy Statement
Ticker: KYTX · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1994702
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: KYTX
TL;DR
Kyverna (KYTX) proxy statement filed. Get ready to vote on company matters.
AI Summary
Kyverna Therapeutics, Inc. filed its definitive proxy statement on April 14, 2025, for its annual meeting of stockholders. The filing covers the fiscal year ending December 31, 2024, and outlines the company's governance and proposals for shareholder votes. The company is based in Emeryville, California.
Why It Matters
This filing provides shareholders with crucial information regarding company governance and upcoming voting matters, allowing them to make informed decisions at the annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 2024 — Fiscal Year End (The proxy statement covers the company's performance and governance for this period.)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- 0000950170-25-053699 (filing_id) — Accession Number
- 20250414 (date) — Filing Date
- 20250529 (date) — Period of Report
- 5980 Horton Street, Suite 550, Emeryville, CA 94608 (address) — Company Business Address
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Kyverna Therapeutics, Inc. to provide shareholders with information for their votes at the annual meeting.
When was this proxy statement filed?
The proxy statement was filed on April 14, 2025.
What is the fiscal year end for Kyverna Therapeutics, Inc. covered by this filing?
The filing covers the fiscal year ending December 31, 2024.
Where is Kyverna Therapeutics, Inc. located?
Kyverna Therapeutics, Inc. is located at 5980 Horton Street, Suite 550, Emeryville, CA 94608.
Is this a preliminary or definitive proxy statement?
This is a definitive proxy statement, as indicated by the filing type and the checkmark next to 'Definitive Proxy Statement'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding Kyverna Therapeutics, Inc. (KYTX).